Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP

Tonix Pharmaceuticals — Technical Presentation (March 2020)

8 slides from Tonix Pharmaceuticals's technical presentation, Mar 20, 2020

  1. Slide 1: WHO Presentation – COVID Vaccine Manufacturers

    1 March 20, 2020 Version P0224 3 - 20 - 20 (Doc 0607) WHO Presentation – COVID Vaccine Manufacturers © 2020 Tonix Pharmaceuticals Holding Corp.

  2. Slide 2: Cautionary Note on Forward-Looking Statements

    Cautionary Note on Forward - Looking Statements © 2020 Tonix Pharmaceuticals Holding Corp. 2 Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looking statements” as defined by the Private Securities Litigat

  3. Slide 3: Public Health and Biodefense Preclinical Pipeline

    © 2020 Tonix Pharmaceuticals Holding Corp. 3 Public Health and Biodefense Preclinical Pipeline 1 1 Experimental new medicines and biologics, not approved for any indication 2 Collaboration with Southern Research 3 Designed to express SARS - CoV - 2 Spike (S) protein 4 COVID - 19 = Coronavirus diseas

  4. Slide 4: Relationship Between Horsepox, Certain Vaccinia Strains and Variola

    4 Relationship Between Horsepox, Certain Vaccinia Strains and Variola Legend: Alignment of orthopoxvirus genomes and location of horsepox (HPXV) genes within telomeres. Orthopoxvirus genomes were aligned using the program GView ( https://server.gview.ca ). The actual nucleotide sequence of each gene

  5. Slide 5: TNX-801 (live horsepox virus vaccine for percutaneous administration)

    TNX - 801 (live horsepox virus vaccine for percutaneous (scarification) administration) © 2020 Tonix Pharmaceuticals Holding Corp. 5 Vaccine based on sequence of isolated horsepox clone 1,2 • No new gene elements and coding sequence is identical to environmental horsepox isolate • May be considered

  6. Slide 6: Potential for Use of Horsepox as a Vector Platform for a Vaccine

    © 2020 Tonix Pharmaceuticals Holding Corp. Potential for Use of Horsepox as a Vector Platform for a SARS - CoV - 2 Vaccine 6 Horsepox can be engineered to express foreign genes and serve as a platform for vaccine development • Large packaging capacity for exogenous DNA inserts (i.e. encoding antigen

  7. Slide 7: TNX-1800 is Designed to Express Spike Protein

    7 TNX - 1800 is Designed to Express SARS - CoV - 2 Spike Protein © 2020 Tonix Pharmaceuticals Holding Corp.

  8. Slide 8: Thank you!

    8 Thank you ! NASDAQ: TNXP © 2020 Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding — Technical Presentation (March 2020) on 6ix